Insulin Efsitora Alfa

What It Is

Insulin efsitora alfa (development code LY3209590; historically 'basal insulin Fc' or BIF; Eli Lilly) is an investigational once-weekly basal insulin. Structurally it is a fusion protein: a novel single-chain variant of the insulin molecule is joined, through a peptide linker, to the fragment-crystallizable (Fc) region of a human immunoglobulin G2 (IgG2) antibody. That Fc domain is the engineering trick behind weekly dosing. It is large enough to slow absorption and clearance, and it engages the neonatal Fc receptor (FcRn), the same salvage pathway that gives antibodies their long life, so the molecule is recycled rather than degraded. The result is a very long half-life - reported at roughly 15 to 17 days - and an unusually flat pharmacodynamic profile, with a low peak-to-trough ratio (about 1.14, i.e. under ~15% fluctuation across the week). Mechanistically efsitora is still just insulin: it binds and activates the insulin receptor, promoting glucose uptake into muscle and fat and suppressing the liver's output of glucose. What differs from daily basal insulins such as glargine (Lantus/Basaglar) and degludec (Tresiba) is the dosing cadence - one subcutaneous injection per week instead of 7 - and, in the type 2 program, a deliberately simplified titration. Efsitora was evaluated in the Phase 3 QWINT program, five parallel trials covering both type 2 and type 1 diabetes. In QWINT-1, 796 insulin-naive adults with type 2 diabetes were randomized to weekly efsitora (using a simple algorithm of four fixed doses) or daily insulin glargine over 52 weeks; efsitora lowered A1C by 1.31% vs 1.27% for glargine (non-inferior), most patients stayed on one of four fixed doses, the median number of dose changes was 2 with efsitora versus 8 with glargine, and clinically significant/severe hypoglycemia was numerically lower (about 0.50 vs 0.88 events per participant-year). QWINT-2 (insulin-naive type 2 diabetes vs degludec) showed A1C reductions of 1.34% vs 1.26%; QWINT-3 (insulin-experienced type 2 diabetes vs degludec, 26 weeks) 0.86% vs 0.75%; and QWINT-4 (type 2 diabetes vs glargine) an equal 1.07% for both. In QWINT-5, in adults with type 1 diabetes, weekly efsitora was non-inferior to daily degludec on A1C but produced a higher rate of level 2/3 hypoglycemia and more severe hypoglycemia (about 10% vs 3% of participants) - a signal that has focused attention on how weekly insulin should be initiated and titrated in the more brittle type 1 setting. Lilly reported the full Phase 3 readouts through 2024-2025 (with QWINT-1 and QWINT-2 published in the New England Journal of Medicine and presented at ADA), and as of mid-2026 insulin efsitora alfa is under FDA review for type 2 diabetes with a decision expected in the third quarter of 2026. If approved it would be the second once-weekly basal insulin to reach the U.S. market conversation, going head-to-head with Novo Nordisk's insulin icodec (Awiqli). Efsitora is a manufactured, physician-prescribed biologic given by injection - not a self-sourced 'research peptide.'

Regulatory Status

Why Researchers Study It

Efsitora is a leading test of whether a full week of basal insulin can be delivered safely in one shot. Reducing 365 basal injections a year to 52 could ease the burden that keeps many people from starting or staying on insulin, and its antibody-Fc design is a template for turning short-lived hormones into once-weekly biologics. Researchers are especially interested in its fixed-dose, low-titration approach for insulin-naive type 2 diabetes, and in the unresolved question of how to dose an ultra-long-acting insulin safely in type 1 diabetes.

Proposed Mechanisms

• Insulin receptor agonist: the single-chain insulin moiety binds and activates the insulin receptor, driving glucose uptake into muscle and adipose tissue and suppressing hepatic glucose production
• Fc-fusion for longevity: fusion of the insulin analog to a human IgG2 Fc fragment via a peptide linker dramatically slows absorption and clearance
• FcRn-mediated recycling: the Fc domain engages the neonatal Fc receptor (the antibody salvage pathway), so the molecule is recycled instead of degraded, extending half-life to roughly 15-17 days
• Flat pharmacodynamics: a low peak-to-trough ratio (about 1.14) produces stable, sustained basal insulin coverage across a full week from a single injection
• Weekly cadence enabling simplified titration: the long, steady exposure supports a fixed-dose adjustment scheme rather than frequent daily dose changes (validated in insulin-naive type 2 diabetes)

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Insulin Efsitora Alfa compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials (June 2025) PubMed
2. [2] Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes (Lilly, Sept 2024) PubMed
3. [3] QWINT-1: Weekly Insulin Efsitora Matches Daily Basal Insulin in Type 2 Diabetes - HCPLive PubMed
4. [4] Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial - Lancet / PubMed PubMed
5. [5] Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa) - Diabetes, Obesity and Metabolism PubMed
6. [6] Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein - JPET PubMed
7. [7] FDA Decisions Expected: July 2026 (insulin efsitora alfa) - Prime Therapeutics PubMed
8. [8] insulin efsitora alfa (Pending FDA Approval) - Medscape PubMed

Related Peptides